Research Article | Open Access
Stefania Bruno, Cristina Grange, Marta Tapparo, Chiara Pasquino, Renato Romagnoli, Ennia Dametto, Antonio Amoroso, Ciro Tetta, Giovanni Camussi, "Human Liver Stem Cells Suppress T-Cell Proliferation, NK Activity, and Dendritic Cell Differentiation", Stem Cells International, vol. 2016, Article ID 8468549, 14 pages, 2016. https://doi.org/10.1155/2016/8468549
Human Liver Stem Cells Suppress T-Cell Proliferation, NK Activity, and Dendritic Cell Differentiation
Human liver stem cells (HLSCs) are a mesenchymal stromal cell-like population resident in the adult liver. Preclinical studies indicate that HLSCs could be a good candidate for cell therapy. The aim of the present study was to evaluate the immunogenicity and the immunomodulatory properties of HLSCs on T-lymphocytes, natural killer cells (NKs), and dendritic cells (DCs) in allogeneic experimental settings. We found that HLSCs inhibited T-cell proliferation by a mechanism independent of cell contact and dependent on the release of prostaglandin E2 (PGE2) and on indoleamine 2,3-dioxygenase activity. When compared with mesenchymal stromal cells (MSCs), HLSCs were more efficient in inhibiting T-cell proliferation. At variance with MSCs, HLSCs did not elicit NK degranulation. Moreover, HLSCs inhibited NK degranulation against K562, a NK-sensitive target, by a mechanism dependent on HLA-G release. When tested on DC generation from monocytes, HLSCs were found to impair DC differentiation and DCs ability to induce T-cell proliferation through PGE2. This study shows that HLSCs have immunomodulatory properties similar to MSCs, but, at variance with MSCs, they do not elicit a NK response.
Human liver stem cells (HLSCs) have been identified and characterized as a mesenchymal stromal cell-like population derived from adult human liver . This population possesses many surface markers in common with bone marrow-derived mesenchymal stromal cells (MSCs) such as CD29, CD73, CD44, CD105, and CD146; in addition, they express specific hepatic cell markers (albumin, cytokeratin-8, and cytokeratin-18) and embryonic markers (Nanog, Oct3/4, Sox2, Musashi, SSEA4, and Pax2) [1, 2]. HLSCs are able to differentiate into osteocytes, endothelial cells, hepatocytes, and beta-like cells [1–3]. When injected in different experimental models of liver failure, HLSCs engraft in injured liver and improve liver function and morphology [1, 2]. In particular, HLSCs have been described to protect SCID mice with fulminant liver failure from death by direct differentiation into hepatocytes and by secreting soluble factors that limit the injury . Moreover, HLSCs are able to improve recovery also of different organs, such as kidneys . Being potential candidates for clinical application, it is important to investigate the immunogenicity of HLSCs and their interaction with the immune system. In fact, a common complication in allogeneic cell therapies is the immune rejection. However, therapy with allogeneic MSCs of different origin is facilitated by their low immunogenicity and immunomodulatory properties [5, 6].
The aim of the present study was to evaluate whether HLSCs could modulate the behavior of immune cells, in comparison with MSCs. In particular, we investigated the effects of HLSCs on T-lymphocytes, natural killer cells (NKs), and dendritic cells (DCs) in allogeneic experimental settings.
2. Materials and Methods
2.1. Culture of HLSCs and MSCs
HLSCs were isolated from human cryopreserved normal adult hepatocytes purchased from Lonza (Basel, Switzerland) and were cultured as described [1–4]. Briefly, hepatocytes were initially cultured for 2 weeks in hepatozyme-SFM medium at a density of 1.0–1.5 × 105 viable cells per cm2. After 2 weeks, most of the hepatocytes died, and then medium was substituted by α-MEM/EBM-1 (3 : 1) (Lonza) media supplemented with l-glutamine (5 mM), HEPES (12 mM, pH 7.4), penicillin (50 IU/mL), streptomycin (50 μg/mL) (all from Sigma, St. Louis, MO, USA), and fetal calf serum (FCS) (10%) (Invitrogen). When HLSC colonies were evident, cells were expanded and characterized. HLSCs expressed some MSC markers (CD29, CD44, CD73, CD90, and CD105), specific hepatic markers (albumin, α-fetoprotein, cytokeratin-8, and cytokeratin-18), and some embryonic stem cell markers (Oct3/4, Nanog, Pax2, Musashi, SSEA4, and Sox2) as previously described [1–3]. By cytofluorimetric analysis (FACS), conducted with FACSCalibur cytometer (Becton Dickinson Bioscience, San José, CA), the expression of costimulatory molecules and histocompatibility antigens, CD40, CD80, CD86, HLA class I, and HLA-DR (all from Becton Dickinson), was evaluated (dilution 1 : 20).
HLSCs obtained from each preparation showed the same phenotype and they were used within the 10th passages.
The expression of human leukocyte antigen G (HLA-G, dilution 1 : 20) on HLSCs was evaluated by FACS analyses using the specific MEMG/9 antibody (native form for human HLA-G1, EXBIO, Praha, Czech Republic). Extracellular staining and intracellular staining were used to study membrane-bound and intracytoplasmic HLA-G protein.
Bone marrow MSCs were purchased from Lonza, cultured, and characterized as previously described .
2.2. Peripheral Blood Mononuclear Cells Isolation
Peripheral blood mononuclear cells (PBMCs) were obtained from healthy donors ( males; female and age 25–40 years old). All subjects gave informed consent and the study was approved by the local Ethical Review Board. PBMCs were isolated by centrifugation over Histopaque-1077 (Sigma).
2.3. T-Cell Purification and Culture
CD3-positive cells were sorted from PBMCs using immunomagnetic beads (Miltenyi Biotec, Cologne, Germany) and used in coculture experiments. PBMCs were characterized to typify HLA Class I and HLA Class II expression (Supplementary Table in Supplementary Material available online at http://dx.doi.org/10.1155/2016/8468549). To this purpose DNA was extracted and Luminex technology was used (One Lambda, Thermo Fisher). Luminex technology uses sequence-specific oligonucleotide probes bound to color-coded microbeads in order to identify HLA alleles encoded by the DNA sample. As shown in Supplementary Table , different donors had different HLA class I and HLA class II phenotype and were mismatched with HLSCs.
The purity of CD3+ was 98 ± 2% assessed by FACS analysis (not shown). CD3+ cells were directly used for coculture experiments or activated with 10 ng/mL of phorbol myristate acetate (PMA, Sigma) or with a mix of CD3 (1 μg/mL, Miltenyi Biotec) and CD28 (2 μg/mL, Miltenyi Biotec) antibodies. Cocultures were established in direct contact or by using transwells (1 μm pore, Falcon, Becton Dickinson) in 6- or 24-well plates (Corning Incorporated, NY, USA). HLSCs and MSCs (1 × 105/wells) were seeded into the lower compartment of the culture wells. Different amounts of lymphocytes were loaded in the upper inserts to obtain ratios of lymphocytes/HLSCs or MSCs of 1 : 1, 2 : 1, 5 : 1, and 10 : 1. In selected experiments, in noncontact conditions, specific chemical antagonists of indoleamine 2,3-dioxygenase (IDO) and of prostaglandin E2 (PGE2) such as 1-methyl-L-tryptophan (an inhibitor of IDO, Sigma, 0.5 mM), indomethacin (Cox-1 and Cox-2 inhibitor, 10 μM, ICN Chemicals, Irvine, CA), and NS-398 (a specific Cox-2 inhibitor, 1 μM, Cayman Chemicals, Ann Arbor, MI) were added to coculture (ratio lymphocytes/HLSCs 5 : 1). All the experiments were conducted in duplicate. The T-cell proliferation analysis was performed, after 3 days of incubation, with the Muse Count & Viability Kit (Millipore, Billerica, MA), following the manufacturer’s instruction, and subsequently analysed by the Muse™ Cell Analyzer (Merck Millipore, Massachusetts, USA). In particular, the Muse Count & Viability Reagent contains fluorescent DNA-binding dyes, which have differential permeability to viable and nonviable cells, and provides absolute cell count and viability data on cell suspensions. Both viable and nonviable cells are differentially stained based on their permeability to the DNA-binding dyes in the reagent. Data generated using the Muse Cell Analyzer with the Muse software provide the viable cell count (cells/mL); the total cell count (cells/mL); and the percentage of viability of sample.
The amount of PGE2 produced by HLSCs, in basal condition and after cocultivation, was evaluated by ELISA (R&D System, Minneapolis, MN).
2.4. NK Purification, Culture, and Degranulation Assay
Nonactivated NKs were obtained using the NK Cell Isolation Kit (Miltenyi Biotec) that is an indirect magnetic labelling system for the isolation of untouched NKs from human PBMC. The purity of NKs after the isolation was 95 ± 3% assessed by FACS analysis (not shown). By this system T-cells, B cells, stem cells, dendritic cells, monocytes, granulocytes, and erythroid cells were depleted using immunomagnetic beads.
After purification, NKs were maintained for 24 hours in the presence of 15 ng/mL of interleukin- (IL-) 15 (Sigma). After this incubation, NKs were cocultured in the presence of or MSCs or HLSCs (ratio NK/MSC or HLSC 5 : 1) by using direct coculture or in the transwell system. In selected experiments, to test the functional role of HLA-G, the specific neutralizing antibody 87-G (10 μg/mL, EXBIO) was added in coculture experiments. After 4 days, NKs were harvested and tested in the degranulation assay. The degranulation assay is a highly sensitive method and its results are strictly correlated with NK cytotoxicity . The surface expression of CD107a (Becton Dickinson) was analysed after 4 hours following activation of purified NKs with target cells (HLSCs, MSCs, and K562, ATCC LGC Standards, Sesto San Giovanni, Italy; original donor: female, 53 years old) at a 1 : 1 ratio in the presence of a FITC labelled CD107a and of GolgiStop™ (Becton Dickinson). The GolgiStop contains monensin that prevents the acidification of endocytic vesicles avoiding the degradation of reinternalized CD107a proteins from the surface. Subsequently, NK cells were stained with APC labelled anti-CD56 (Becton Dickinson) and analysed by FACS to measure the percentage of CD107a positivity, as described [7, 8]. In addition, the viability of HLSCs and MSCs was tested using the Muse Annexin V & Dead Cell Kit (Millipore), which permits enumeration of cells in various stage of apoptosis (early and late). The viability of K562 cells was evaluated by staining with propidium iodide (PI, 5 μg/mL, Sigma). In this case, the K562 cells were labelled with green fluorescent dye carboxyfluorescein diacetate succinimidyl ester (CFSE, Molecular Probes, Invitrogen), to discriminate K562 green cells from NKs cells by FACS analyses.
2.5. Human Monocyte Isolation and Differentiation in DCs
Monocytes were isolated by plastic adherence. PBMCs were plated at a concentration of 5 × 106 cell/mL in RPMI supplemented with 10% FCS in 6-well flat-bottomed plates and left to adhere in a 5% CO2 incubator at 37°C overnight. Nonadherent cells were removed by 2 consecutive washes with RPMI plus 10% FCS .
The next day, the DC differentiation medium, composed by RPMI supplemented with 10% FCS, 20 ng/mL of IL-4 (Sigma), and 50 ng/mL of granulocyte-macrophage colony-stimulating factor (GM-CSF, Sigma), was added. The purity of the monocyte population was quantified through FACS analyses, by positive staining for CD14 (87 ± 7%, not shown). Monocytes were cocultured in the presence of 1 × 105 HLSCs or MSCs seeded in transwells (1 µm pore). After 2 days 1/3 of the medium was replaced and after 4 days 200 ng/mL of lipopolysaccharide (LPS, Sigma) was added to the culture. Complete differentiation was reached after 7 days. The same experimental setting was repeated in the presence of NS-398 (1 μM). The amount of PGE2 produced after cocultivation was evaluated by ELISA.
The DC differentiation was assessed after 7 days of culture using FITC, PE, and APC conjugated antibodies (all from Becton Dickinson) for CD14, CD80, CD83, CD86, HLA-DR, CD1a, CD40, CD54, α4 integrin, and α5 integrin. Data were expressed as percentage of positive cells ± SD and as geometric mean of fluorescence intensity ± SD.
Completely differentiated DCs in the presence or the absence of HLSCs were treated with 50 µg/mL of mitomycin C (Sigma) in order to block their proliferation and cultured in triplicate at a concentration of 2 × 104 in 96-well flat-bottomed plate (Corning Incorporated) with 1 × 105 allogeneic CD3+ lymphocytes. As controls, CD3+ cells were cultured alone or were treated with 10 ng/mL of PMA to induce T-cell proliferation. Proliferation rates were analysed after 2 days of coculture using 5-bromo-2′-deoxyuridine (BrdU) incorporation Kit (Roche, Basel, Switzerland). DNA synthesis was detected as incorporation of BrdU into cellular DNA. After 3 days of incubation, cells were then fixed with 0.5 M ethanol/HCl and incubated with nuclease to digest the DNA. BrdU incorporated into the DNA was detected using an anti-BrdU peroxidase-conjugated mAb and visualized with a soluble chromogenic substrate. Optical density was measured with an ELISA reader at 405 nm.
2.6. RNA Extraction and Real Time Analysis
RNA was extracted by Trizol (Life Technology, Carlsbad, CA) and 200 ng of total RNA was retrotranscribed using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). RT-PCR mix containing 1x SYBR GREEN PCR Master Mix (Applied Biosystems), 100 nM of each primer, listed in Table 1, and 5 ng of cDNA were assembled using a 96-well StepOne Real Time System (Applied Biosystems). Negative cDNA controls (no cDNA) were cycled in parallel with each run.
Data are expressed as relative quantification using the method. Normalization was made using actin as housekeeping gene (Table 1).
2.7. Western Blot and Immunoprecipitation for HLA-G
HLSCs were lysed for 15 minutes in a cold buffer containing 1% Igepal, 5 mM EDTA, 150 mM NaCl, 50 mM Tris-HCl (pH 8,0), 1 mM phenylmethylsulfonyl fluoride (PMSF), and a cocktail of protease and phosphatase inhibitors (all from Sigma). Western blots were performed on 10% SDS-PAGE (Bio-Rad, Hercules, CA). Nitrocellulose membranes (Bio-Rad Laboratories) were probed with Abs specific for HLA-G (1 : 200) and actin (1 : 300) (both from Santa Cruz Biotechnology) and with anti-mouse or anti-rabbit horseradish peroxidase- (HRP-) conjugated secondary Abs (1 : 3000) (Pierce, Waltham, MA) and developed using ECL plus detection reagents (GE Healthcare, Piscataway, NJ). Densitometry analysis was performed using Quantity One image acquisition and analysis software (Bio-Rad Laboratories).
For immunoprecipitation analysis, the supernatants collected from HLSCs were subjected to isopropanol precipitation (1 : 4) overnight at −80°C and then lysed with Ripa buffer. Secondary antibodies were preincubated with protein A/G plus agarose (Santa Cruz Biotechnology, Dallas, Texas, USA) for 1 h at 4°C to exclude nonspecific binding of proteins. The tagged proteins were immunoprecipitated with appropriate antibodies for 1 h at 4°C and then with protein A/G plus agarose overnight in a rotor at 4°C. After centrifugation for 3 times in freshly prepared NP-40 buffer (50 mM Tris-HCl, 250 mM NaCl, 2 mM EDTA, 50 mM NaF, and 0,1 mM Na3VO4), the pellets were used for SDS-PAGE (4%–20% acrylamide gel, Bio-Rad).
2.8. Statistical Analyses
Statistical analysis was performed with SPSS (IBM SPSS Statistics, version 20.0.0). Continuous variables are presented as mean ± standard deviation or as median (min-max), according to their distribution. The difference between groups was analysed with Student’s -test (unpaired, 2-tailed), one-way ANOVA, or ANOVA with Dunnet’s multiple comparison test and, when necessary, with Bonferroni correction or with the nonparametric Wilcoxon test. Significance level for all tests was set at .
3.1. HLSCs Suppress T-Cell Proliferation In Vitro
HLSCs are similar to MSCs in that they constitutively express HLA class I antigens but do not express HLA-DR and CD40, CD80, and CD86 costimulatory molecules.
To determine the capacity of HLSCs to interfere with T-lymphocyte proliferation, HLSCs were cocultured with allogeneic CD3+ cells activated or not with PMA. No proliferation was noted when purified T-lymphocytes were cocultured in the presence of HLSCs or MSCs, at different ratios (Supplementary Figure ). Indeed, after 3 days of coculture, HLSCs inhibited PMA-induced CD3+ cell proliferation in a dose-dependent manner. In cell contact conditions, at a 5 : 1 lymphocyte : stem cell ratio, and in the presence of transwells, the inhibitory effect of HLSCs was significantly greater than that of MSCs (Figure 1(a) and Supplementary Figure ). Cell contact was not required for HLSC suppression of T-cell proliferation, as HLSCs separated by a transwell were almost as effective as those in direct contact with lymphocytes (Figure 1(a) and Supplementary Figure ). To confirm the capacity of HLSCs to interfere with T-cell proliferation, we also stimulated transwell cultures with anti-CD3 and CD28 antibodies and observed an inhibition of T-cell proliferation in the presence of HLSCs at different cell ratios (Supplementary Figure ).
The immunomodulatory effect of MSCs has been previously related to the production of two key soluble factors IDO and PGE2. To investigate the relevance of these factors in HLSC suppression of T-cell proliferation, chemical antagonists were added to lymphocyte-HLSC transwell cocultures. The addition of 1-methyl-L-tryptophan (IDO-inhibitor) or indomethacin (Cox-1 and Cox-2 inhibitor) or NS-398 (Cox-2 inhibitor) significantly restored T-cell proliferation (Figure 1(c)). In the absence of HLSCs, these inhibitors did not interfere with T-lymphocyte proliferation (not shown). These data indicated that cell contact was not required and that Cox and IDO played a relevant role in the HLSC-induced suppression of T-cell proliferation. We therefore examined the mRNA levels of Cox-1 and Cox-2 and IDO in HLSCs and MSCs in basal condition and after coculture, in the presence of transwells. HLSCs constitutively expressed Cox-1 (Threshold cycle, Ct: 21 ± 1.2) and IDO (Ct: 31 ± 5.10). Moreover, Cox-1 expression is significantly more expressed in HLSCs in comparison with MSCs (Figure 1(g)). In both HLSCs and MSCs, the expression of Cox-2 and IDO mRNAs significantly increased after coculture with lymphocytes activated with PMA or with CD3 and CD28 antibodies (Figures 1(c)–1(f)). Nonactivated lymphocytes did not induce upregulation of mRNA expression levels of Cox-2 and IDO. We also tested if PMA might influence the expression levels of Cox-2 and IDO in HLSCs and MSCs. As shown in Figures 1(c)–1(f), PMA did not significantly increase the expression levels of Cox-2 and IDO. Instead, the conditioned medium (CM) derived from T-cells stimulated with PMA induced a significant increase in both MSCs and HLSCs. PGE2 production also significantly increased after culture with lymphocytes (Figure 1(h)). Stimulated T-lymphocytes in the absence of HLSCs did not produce PGE2 (Figure 1(h)).
3.2. HLSCs Do Not Stimulate NK Degranulation
In order to compare the susceptibility of HLSCs to NK cell-mediated lysis, a degranulation assay was performed based on the detection of CD107a surface molecules on NK cell membranes, after NK-HLSC coculture. Allogeneic NKs were stimulated for 24 hours with IL-15 to increase their cytotoxic potential. Both HLSCs and MSCs were used as target cells. Figure 2(a) shows that, after 4 hours of incubation, degranulation of NKs in response to HLSCs was absent (CD56+CD107+: 1 ± 0.5%). In contrast, MSCs induced NK degranulation (CD56+CD107+: 9.3 ± 3.2%), as previously described [8, 10, 11]. Moreover, the viability of HLSCs and MSCs was evaluated after 4 hours of incubation with IL-15 activated NKs. In these conditions, the percentage of early apoptotic HLSCs did not significantly increase, whereas the percentage of early apoptotic MSCs significantly increased (Figure 2(b)), confirming the data obtained by degranulation assay. No significant difference was observed in the percentage of late apoptotic cells between HLSCs and MSCs.
3.3. HLSCs Impair NK Function on Target Cells
To study whether HLSCs modulated NK activity, coculture experiments were carried out in direct contact or by using transwell inserts. Prestimulated NKs were cocultured with HLSCs or MSCs and subsequently harvested to evaluate the degranulation capacity against K562, a susceptible target cell line. K562 cells induced degranulation of NKs prestimulated with IL-15 (CD56+CD107+: 65 ± 8% (Figure 3(a))). Preincubation of NKs with HLSCs, in contact condition or in the presence of transwell, was able to significantly decrease NK degranulation (CD56+CD107+: resp., 8.2 ± 1.5% and 2.5 ± 2%), in a manner comparable with the preincubation with MSCs (CD56+CD107+: resp., 5.3 ± 2.2% and 7 ± 3%) (Figure 3(b)). Moreover, after incubation with HLSCs, NKs decreased their capacity to kill K562 cells (Figures 3(c) and 3(e)) and confirmed the data obtained by the degranulation test. Also NKs incubated with MSCs decreased their capacity to kill K562 cells (Figures 3(c) and 3(d)), but to a lesser extent than HLSCs (Figure 3(e)).
We investigated whether the expression of HLA-G molecule on HLSCs was involved in HLSC-induced inhibition of NKs. Intracellular HLA-G was detected by flow cytometry in HLSCs (69 ± 3.5%; Figure 4(a)) while only 10% of cells were positive for membrane-bound HLA-G staining. Western Blot analyses confirmed the presence of HLA-G in HLSCs at different passages of culture (Figure 4(b)). Soluble HLA-G was also present in HLSC supernatants (Figure 4(c)). Experiments with blocking antibody against HLA-G in transwells suggest that soluble HLA-G released by HLSCs is involved in the inhibitory effect on NK activity (Figure 4(d)).
3.4. HLSCs Suppress Monocyte-Derived DC Differentiation and Maturation
Monocytes were cultured with GM-CSF and IL-4 in the presence or the absence of HLSCs or MSCs. After 4 days of culture, LPS was added to promote the complete differentiation of DCs. After 7 days of differentiation in these culture conditions, monocytes acquired the characteristic shape and morphology of DCs and their degrees of differentiation and maturation were assessed by FACS analyses. In DCs that differentiated in the absence of HLSCs and MSCs, the expression of CD14 (6 ± 4.8% of positive cells) surface marker was almost abrogated; CD80, CD86, and HLA-DR expression was high (72 ± 10%, 87 ± 8.6%, and 93 ± 6.9%, resp.) and the activation markers CD1a and CD40 were increased (87 ± 6.4%, 23 ± 15.0%, resp.) (Supplementary Figure and Figure 5(a)). The presence of HLSCs cultured in transwells interfered the differentiation process of DCs, as shown by the persistence of CD14 (58 ± 10.5%) expression on monocyte-derived cells (Supplementary Figure and Figure 5(a)) and inhibition of the differentiation and maturation markers such as CD80 (38 ± 16.1%), CD86 (37 ± 20.3%), HLA-DR (51 ± 21.3%), CD1a (45 ± 16.0%), and CD40 (2.8 ± 2.0%). Moreover, the expression of α4 integrin and α5 integrin adhesion molecules and CD54 decreased in the presence of HLSCs (Supplementary Figure and Figure 5(a)). The mean fluorescence intensity (GEO mean) was also analysed for several surface markers. The intensity for CD80, CD86 and HLA-DR, CD54, and α5 integrin was significantly lower in DCs cultured with HLSCs compared with DCs differentiated in the absence of stem cells (Figure 5(b)). The effect of HLSCs on DC differentiation was comparable to that previously described for MSCs (Figures 5(a) and 5(b)) [12, 13]. Notably, the presence of HLSCs did not affect DCs viability (not shown) as already demonstrated for MSCs .
DCs promote antigen-specific T-cell activation. DCs stimulated with LPS were able to induce CD3+ lymphocyte proliferation. When DCs predifferentiated in the presence of HLSCs were used, a significant reduction of T-cell proliferation was observed (Figure 5(c)). These results confirm functional impairment of DC differentiation in the presence of HLSCs.
The action of MSCs on DC differentiation has been ascribed to the production of many soluble factors, of which the most important seems to be PGE2 . The presence of PGE2 was quantified by ELISA assay in supernatant of DCs differentiated in the presence or the absence of HLSCs (3 and 7 day of culture) and in HLSC supernatant (Figure 6(a)). As shown in Figure 6(a), HLSCs produced PGE2 constitutively; moreover, the amount of this mediator was significantly increased in coculture with DCs. DCs cultured alone did not produce PGE2 (Figure 6(a)). mRNA levels of Cox-1 and Cox-2 were evaluated in HLSCs and DCs when cocultured. mRNA levels of Cox-1 and Cox-2 were significantly higher in HLSCs compared with DCs, suggesting that PGE2 was mainly secreted by HLSCs (Figure 6(b)).
In addition, to test the biological role of PGE2, NS-398 was added to DC culture in the presence of HLSCs. PGE2 inhibition significantly reverted the negative effect of HLSCs on DC differentiation (Figure 6(c)). Taken together, these data suggest that PGE2 plays a central role in the inhibition of DC function.
HLSCs are a population of liver stem-like cells easily obtainable from human adult liver [1–3]. They have a great proliferation potential and remain stable for over thirtieth culture passages, without acquiring chromosomal aberrations. Good manufacturing practice protocols to obtain and expand HLSCs have been established in our laboratory. Moreover, HLSCs have been approved by Italian Regulatory Agency for a phase I study, fulfilling all the release criteria for cellular therapies.
A critical issue in cell therapy is rejection, resulting from the immune-incompatibility between donor and recipient. In this paper, we show that HLSCs have immunomodulatory properties that may obviate the major obstacle for the application of these cells in cell therapy.
HLSCs did not express HLA class II and the costimulatory molecules CD40, CD80, and CD86. In addition, HLSCs inhibit (i) proliferation of mitogen-stimulated T-lymphocytes in a dose-dependent manner, (ii) degranulation capacity of NKs against a susceptible target cancer cell line, and (iii) DC differentiation and maturation.
The inhibitory effect of HLSCs on T-lymphocyte proliferation was dose-dependent (ratio lymphocytes to stem cells: 1 : 1, 2 : 1, 5 : 1, and 10 : 1) and was greater than that of MSCs. HLSC-dependent inhibition of T-cell proliferation was observed with a ratio up to 10 : 1. Furthermore, cell contact was not required for this effect, as HLSCs separated by a transwell were almost as effective as those in direct contact with lymphocytes. The mechanisms responsible for the suppression of T-lymphocyte proliferation also have been evaluated. HLSCs constitutively expressed Cox-1 and IDO; their mRNA levels increased after coculture with T-lymphocytes. Moreover, the addition of chemical antagonists of these enzymes significantly restored T-cell proliferation, indicating that Cox and IDO activities are involved in the antiproliferative effect of HLSCs. These observations are similar to that reported for MSCs [7, 15, 16]. It has been shown that PGE2 synthesis inhibition mitigated MSC-mediated suppression of T-lymphocytes [16, 17] and that IDO activity was involved in MSC-induced inhibition of T-cell proliferation .
Furthermore, it was found that HLSCs did not elicit a significant NK response. In contrast, MSCs were sensitive to NK as they induced high NK degranulation [8, 10, 11]. Therefore, HLSCs seem to be more protected than MSCs from allogeneic NK lysis. MSCs from other sources such as adipose tissue and embryonic stem cells have been also shown to be more resistant to NK lyses than bone marrow MSCs [8, 18, 19]. This may represent an advantage for their application in cellular therapies.
Another important aspect to be considered, related to NK/HLSC interaction, was whether the NKs cocultured with HLSCs modify their functionality over other susceptible target cells. The degranulation capacity of NKs on K562 cancer cell line was reduced after coculture with HLSCs also in the absence of contact. Similar inhibition of NK degranulation on target cells was observed for MSCs . Previous studies demonstrated that the secretion of soluble HLA-G plays an important role in the biological effect of MSCs [20, 21]. HLA-G is a nonclassical HLA class I molecule with low polymorphism and a restricted tissue distribution (e.g., trophoblasts). HLA-G is known to confer to the fetus protection against the maternal immune system . The addition of the specific blocking antibody against HLA-G to the NK/HLSC coculture prevented the inhibitory effect of HLSCs on NK degranulation. This observation, together with the presence of soluble HLA-G in HLSC supernatant, suggests a possible role of this molecule in NK modulation.
The effect of HLSCs on DC differentiation was also comparable to that previously described for MSCs [11–13, 23]. In the presence of HLSCs, the differentiation of CD14+ monocytes into DCs was impaired. In the appropriate culture condition and in the presence of HLSCs, monocytes retained the expression of CD14 and did not upregulate specific dendritic markers of maturation and activation. The addition of a specific PGE2 inhibitor reverted this effect suggesting that PGE2 secreted by HLSCs plays a central role in the inhibitory effect of HLSCs on DC differentiation. In addition, HLSCs also efficiently suppressed the ability of DCs to stimulate T-cell-activation and proliferation.
The immunomodulatory effect of HLSCs in physiological conditions is hard to demonstrate in vivo as this population has been described only in humans. In addition, the ratio of HLSCs/lymphocytes used in vitro possible does not represent ratio present in the human liver. However, if used therapeutically, the amount of HLSCs administered may account for an in vivo immunomodulatory effect as shown for MSCs which in patients with graft versus host disease are repeatedly injected at doses in the range of 1–1.5 × 106 cells/Kg [24, 25].
The results of the present study indicate that HLSCs display optimal characteristics for cell therapy in an allogeneic setting. In fact, they modulate different aspects of the immune response including immunogenicity and T and NK responses. These results may be relevant for cell transplantation since these cells received the Orphan Drug designation from the European Medical Agency for ornithine transcarbamylase deficiency (EU/3/11/904), carbamoyl-phosphatase synthase deficiency (EU/3/12/971), and acute liver failure (EU/3/12/983).
|HLSCs:||Human liver stem cells|
|MSCs:||Mesenchymal stromal cells|
|NKs:||Natural killer cells|
|PBMCs:||Peripheral blood mononuclear cells|
|PMA:||Phorbol myristate acetate|
Giovanni Camussi and Ciro Tetta are named inventors in a patent relative to HLSCs (ES2355327-T3). Ciro Tetta is a full-time employee of Fresenius Medical Care. Ciro Tetta and Giovanni Camussi are named inventors in related patents. The other authors declare that they have no competing interests.
Stefania Bruno, Cristina Grange, Marta Tapparo, Chiara Pasquino, and Giovanni Camussi contributed to conception and design, acquisition of data, and analysis and interpretation of data. Ennia Dametto and Antonio Amoroso performed genetic analyses. Stefania Bruno, Cristina Grange, and Giovanni Camussi have been involved in drafting the paper. Renato Romagnoli and Ciro Tetta revised critically the paper. All the authors read and approved the final paper and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
This study was supported by Stem-Liver grant of Fresenius Medical Care, Germany. The authors thank Dr. Fabrizio Fop for statistical analyses.
Supplementary Table 1. Phenotype of HLA I and II of HLSCs and of PBMCs derived from different healthy donors.
Supplementary Figure 1. HLSCs suppress T-lymphocyte proliferation induced by PMA.
Supplementary Figure 2. HLSCs suppress T-lymphocyte proliferation induced by CD3/CD28 antibodies.
Supplementary Figure 3. HLSCs suppress monocyte-derived DC differentiation.
- M. B. Herrera, S. Bruno, S. Buttiglieri et al., “Isolation and characterization of a stem cell population from adult human liver,” Stem Cells, vol. 24, no. 12, pp. 2840–2850, 2006.
- M. B. Herrera, V. Fonsato, S. Bruno et al., “Human liver stem cells improve liver injury in a model of fulminant liver failure,” Hepatology, vol. 57, no. 1, pp. 311–319, 2013.
- V. Fonsato, M. B. Herrera, S. Buttiglieri, S. Gatti, G. Camussi, and C. Tetta, “Use of a rotary bioartificial liver in the differentiation of human liver stem cells,” Tissue Engineering Part C: Methods, vol. 16, no. 1, pp. 123–132, 2010.
- M. B. H. Sanchez, S. Bruno, C. Grange et al., “Human liver stem cells and derived extracellular vesicles improve recovery in a murine model of acute kidney injury,” Stem Cell Research and Therapy, vol. 10, p. 124, 2014.
- M. Di Trapani, G. Bassi, M. Ricciardi et al., “Comparative study of immune regulatory properties of stem cells derived from different tissues,” Stem Cells and Development, vol. 22, no. 22, pp. 2990–3002, 2013.
- M. D. Griffin, T. Ritter, and B. P. Mahon, “Immunological aspects of allogeneic mesenchymal stem cell therapies,” Human Gene Therapy, vol. 21, no. 12, pp. 1641–1655, 2010.
- G. Alter, J. M. Malenfant, and M. Altfeld, “CD107a as a functional marker for the identification of natural killer cell activity,” Journal of Immunological Methods, vol. 294, no. 1-2, pp. 15–22, 2004.
- O. DelaRosa, B. Sánchez-Correa, S. Morgado et al., “Human adipose-derived stem cells impair natural killer cell function and exhibit low susceptibility to natural killer-mediated lysis,” Stem Cells and Development, vol. 21, no. 8, pp. 1333–1343, 2012.
- E. Elkord, P. E. Williams, H. Kynaston, and A. W. Rowbottom, “Human monocyte isolation methods influence cytokine production from in vitro generated dendritic cells,” Immunology, vol. 114, no. 2, pp. 204–212, 2005.
- P. A. Sotiropoulou, S. A. Perez, A. D. Gritzapis, C. N. Baxevanis, and M. Papamichail, “Interactions between human mesenchymal stem cells and natural killer cells,” STEM CELLS, vol. 24, no. 1, pp. 74–85, 2006.
- G. M. Spaggiari, A. Capobianco, S. Becchetti, M. C. Mingari, and L. Moretta, “Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation,” Blood, vol. 107, no. 4, pp. 1484–1490, 2006.
- X.-X. Jiang, Y. Zhang, B. Liu et al., “Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells,” Blood, vol. 105, no. 10, pp. 4120–4126, 2005.
- W.-H. Liu, J.-J. Liu, J. Wu et al., “Novel mechanism of inhibition of dendritic cells maturation by mesenchymal stem cells via interleukin-10 and the JAK1/STAT3 signaling pathway,” PLoS ONE, vol. 8, no. 1, Article ID e55487, 2013.
- G. M. Spaggiari, H. Abdelrazik, F. Becchetti, and L. Moretta, “MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2,” Blood, vol. 113, no. 26, pp. 6576–6583, 2009.
- R. Meisel, A. Zibert, M. Laryea, U. Göbel, W. Däubener, and D. Dilloo, “Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation,” Blood, vol. 103, no. 12, pp. 4619–4621, 2004.
- I. Rasmusson, O. Ringdén, B. Sundberg, and K. Le Blanc, “Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms,” Experimental Cell Research, vol. 305, no. 1, pp. 33–41, 2005.
- S. Aggarwal and M. F. Pittenger, “Human mesenchymal stem cells modulate allogeneic immune cell responses,” Blood, vol. 105, no. 4, pp. 1815–1822, 2005.
- A. Ribeiro, P. Laranjeira, S. Mendes et al., “Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrow exhibit different capability to suppress peripheral blood B, natural killer and T cells,” Stem Cell Research and Therapy, vol. 4, no. 5, article no. 125, 2013.
- B. L. Yen, J. C. Chan, K.-J. Liu et al., “Human embryonic stem cell-derived mesenchymal progenitors possess strong immunosuppressive effects toward natural killer cells as well as T lymphocytes,” STEM CELLS, vol. 27, no. 2, pp. 451–456, 2009.
- Z. Selmani, A. Naji, I. Zidi et al., “Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+ CD25highFOXP3+ regulatory T cells,” Stem Cells, vol. 26, no. 1, pp. 212–222, 2008.
- A. Nasef, N. Mathieu, A. Chapel et al., “Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G,” Transplantation, vol. 84, no. 2, pp. 231–237, 2007.
- N. Rouas-Freiss, R. M.-B. Gonçalves, C. Menier, J. Dausset, and E. D. Carosella, “Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 21, pp. 11520–11525, 1997.
- Y. Zhang, W. Cai, Q. Huang et al., “Mesenchymal stem cells alleviate bacteria-induced liver injury in mice by inducing regulatory dendritic cells,” Hepatology, vol. 59, no. 2, pp. 671–682, 2014.
- M. Introna, G. Lucchini, E. Dander et al., “Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients,” Biology of Blood and Marrow Transplantation, vol. 20, no. 3, pp. 375–381, 2014.
- F. Sánchez-Guijo, T. Caballero-Velázquez, O. López-Villar et al., “Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease,” Biology of Blood and Marrow Transplantation, vol. 20, no. 10, pp. 1580–1585, 2014.
Copyright © 2016 Stefania Bruno et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.